Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT04793958	TitlePhase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)	Phase Phase 3	Date Added 2021-03-11	Location Alabama, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Argentina Australia Austria Belgium Brazil Canada China Colombia Czechia Denmark Finland France Germany Greece Hong Kong Ireland Italy Korea, Republic of Malaysia Mexico Netherlands Poland Portugal Puerto Rico Romania Singapore Spain Taiwan Thailand Ukraine United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs cetuximab, FOLFIRI Regimen, mFOLFOX6 Regimen, MRTX849	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04776148	TitleStudy of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)	Phase Phase 3	Date Added 2021-03-01	Location California, United States Georgia, United States Illinois, United States Maryland, United States Michigan, United States Montana, United States Oregon, United States Pennsylvania, United States Virginia, United States Washington, United States Argentina Australia Canada China Denmark Germany Israel Japan Russia South Korea Spain Taiwan Turkey (Türkiye) United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Completed	Drugs Lenvatinib, Pembrolizumab, Regorafenib, TAS-102 (trifluridine and tipiracil)	Tags MSS/ MMRp
NCT ID NCT04730544	TitleEfficacy and Safety of Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI Metastatic Colorectal Cancer ( NIPISAFE )	Phase Phase 2	Date Added 2021-01-29	Location France	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Ipilimumab, Nivolumab	Tags MSI-H/ MMRd
NCT ID NCT04724239	TitleA Study of Sintilimab and Chidamide in Combination With or Without IBI305 in Standard Treatment Failure of Advanced or Metastatic pMMR/MSS Colorectal Carcinoma	Phase Phase 2	Date Added 2021-01-26	Location China	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs chidamide, IBI305, Sintilimab	Tags MSS/ MMRp
NCT ID NCT04708470	TitlePhase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer	Phase Phase 1, Phase 2	Date Added 2021-01-14	Location Maryland, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Bintrafusp alfa, Entinostat, NHS-IL12	Tags MSS/ MMRp
NCT ID NCT04687631	TitleConversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases	Phase Phase 3	Date Added 2020-12-29	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs mFOLFOXIRI Plus Bevacizumab, mFOLFOXIRI plus Cetuximab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04660812	TitleAn Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.	Phase Phase 1, Phase 2	Date Added 2020-12-09	Location Arizona, United States California, United States Connecticut, United States District of Columbia, United States Georgia, United States Louisiana, United States Maryland, United States Missouri, United States Nevada, United States New York, United States South Carolina, United States Tennessee, United States Texas, United States Wisconsin, United States France Italy South Korea Spain United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Completed	Drugs AB680, Bevacizumab, Etrumadenant, mFOLFOX-6 regimen, Regorafenib, Zimberelimab	Tags MSS/ MMRp
NCT ID NCT04659382	TitleStudy to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer	Phase Phase 2	Date Added 2020-12-09	Location France	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Atezolizumab, Bevacizumab, TheraSphere, XELOX	Tags MSS/ MMRp
NCT ID NCT04653480	TitleSurufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC	Phase Phase 2	Date Added 2020-12-04	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Chemotherapy, Surufatinib, Toripalimab	Tags MSS/ MMRp
NCT ID NCT04626635	TitleREGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors	Phase Phase 1, Phase 2	Date Added 2020-11-12	Location California, United States Colorado, United States Florida, United States Illinois, United States Iowa, United States Massachusetts, United States Michigan, United States New Jersey, United States New York, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States France Israel Netherlands Poland Spain Turkey (Türkiye)	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs cemiplimab, REGN7075	Tags MSS/ MMRp

Showing 141 to 150 of 299 entries